What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 922048

Cover Image

PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 922048

Patient Derived Xenograft Models Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

PAGES: 115 Pages
DELIVERY TIME: 2-3 business days
PDF & Excel (Single User License)
USD 4750
PDF & Excel (Team License: Up to 7 Users)
USD 5250
PDF & Excel (Site License)
USD 6500
PDF & Excel (Corporate License)
USD 8750

Add to Cart

Xenograft animal models are used to test the efficacy of medicines. They are primarily used for screenings and drug development for cancer, diabetes, infections, etc. Factors such as growing demand for personalized medicine, rising R&D activities in the pharmaceutical industry and continuous support for cancer research from the public as well as the private sector are driving the growth of the patient-derived xenograft models market. The mouse model of cancer has consistently been used to determine the in vivo activity of new anti-cancer therapeutics prior to clinical development and testing in humans. According to the World Cancer Research Fund, in 2018, there were around 18 million cancer cases worldwide. This leads to increased support from the public as well as the private sector associated with cancer research. Hence, the growing focus toward the development of better treatment options, along with the increasing burden of cancer is expected to drive the patient-derived xenograft models market.

However, the high cost of personalized PDX models is expected to restrain the growth of the global market in the forecast period.

Key Market Trends

Respiratory Tumor Model Segment is Expected to Show Better Growth in the Forecast Period

Based on tumor type, the market is segmented into the gastrointestinal tumor model, gynecological tumor model, respiratory tumor model, and other tumor models. The respiratory tumor model segment is expected to grow at a faster pace during the forecast period. The key factor contributing to the growth of the segment include the growing research activities in the field of oncology and increasing focus of market players on generating lung cancer PDX models, along with the rising number of cancer cases. According to WHO, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Many companies are focusing on developing breakthrough products for the treatment of chronic disease in order to maintain their competitive advantage and penetrate new regional markets. Additionally, the increase in funding for companies involved in cancer research is expected to boost the studied market.

North America leads the Patient Derived Xenograft Models Market

North America leads the patient-derived xenograft models market owing to a rise in funding initiatives and awareness among patients regarding personalized medicine, followed by Europe. Patient-derived tumor xenografts are recognized as very relevant preclinical cancer models. As per American Cancer Society estimates, in 2018, there were 1,735,350 new cases of cancer diagnosed in the United States. Also, in 2018, the National Institute of Cancer expands the repository of cancer research models to include more research models. Hence, the North America region is expected to grow at a faster rate due to rising preclinical activities by pharmaceutical companies, and growing cancer research in this region.

Competitive Landscape

The leading players in the global Patient Derived Xenograft Models Market are Champions Oncology, Inc., Crown Bioscience, Inc., Charles River Laboratories, Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Urolead and Xentech.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 67577



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Demand for Personalized Medicine
    • 4.2.2 Rising R&D Activities in the Pharmaceutical Industry
    • 4.2.3 Continuous Support for Cancer Research From Public as Well as Private Sector
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Personalized PDX Models
    • 4.3.2 Stringent Regulations Towards Use of Animals Models
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Mice Model
    • 5.1.2 Rats Model
  • 5.2 By Tumor Type
    • 5.2.1 Gastrointestinal Tumor Model
    • 5.2.2 Gynecological Tumor Model
    • 5.2.3 Respiratory Tumor Model
    • 5.2.4 Other Tumor Model
  • 5.3 By End User
    • 5.3.1 Pharmaceutical & Biotechnology Companies
    • 5.3.2 Academic & Research Institutions
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Rest of the World


  • 6.1 Company Profiles
    • 6.1.1 Champions Oncology, Inc.
    • 6.1.2 Charles River Laboratories, Inc.
    • 6.1.3 Crown Bioscience, Inc.
    • 6.1.4 EPO Berlin-Buch GmbH
    • 6.1.5 Hera BioLabs
    • 6.1.6 Horizon Discovery Group plc,
    • 6.1.7 Oncodesign
    • 6.1.8 Pharmatest Services Ltd
    • 6.1.9 Urolead
    • 6.1.10 Xentech


Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!